PCV1 ZIPRASIDONE VS OLANZAPINE: CONTRASTS IN CHD RISK: PCVI  by Leaderer, M et al.
318 Abstracts
CARDIOVASCULAR DISEASE (including Obesity)
CARDIOVASCULAR DISEASE (including Obesity)—
Clinical Outcomes Studies
PCV1
ZIPRASIDONE VS OLANZAPINE: CONTRASTS IN CHD RISK
Leaderer M, Harrison DJ, Loebel A, Murray S
Pﬁzer Inc, New York, NY, USA
OBJECTIVES: To examine the differences in coronary heart
disease (CHD) risk arising from short-term treatment with the
atypical antipsychotics ziprasidone and olanzapine. METHODS:
Hospitalized schizophrenic adult patients underwent 6 weeks¢
randomized, double-blind treatment with ziprasidone or olanza-
pine, with data collected at baseline and endpoint for fasting
lipids and weekly for blood pressure (BP). A published Fram-
ingham algorithm was used to calculate the percentage CHD risk
that would be incurred over 10 years in patient’s ≥ 30 years (per
algorithm). Baseline-to-endpoint LS mean changes in age-
adjusted risk by sex were compared using ANCOVA (baseline
adjusted). RESULTS: In men, baseline-to-endpoint changes in
total cholesterol (TC) and low-density lipoprotein cholesterol
(LDL-C) were signiﬁcant for olanzapine (n = 56; +22.7 and
+13.9mg/dL, respectively) versus ziprasidone (n = 50; -10.0 and
-6.9mg/dL, respectively) (P < 0.01 for TC, P < 0.05 for LDL-
C). CHD risk in men increased by 0.8% (from a baseline of
4.2%) with olanzapine (n = 55) and decreased by 0.2% (from a
baseline of 4.5%) with ziprasidone (n = 46) (P < 0.05 between
groups). In women, between-group differences were insigniﬁcant
for lipid changes and CHD risk. Neither treatment had signiﬁ-
cant effects on BP. CONCLUSIONS: In short-term treatment 
of men, olanzapine caused signiﬁcant changes in lipid proﬁle
versus ziprasidone, with a consequent signiﬁcant increase in
CHD risk versus ziprasidone. These ﬁndings, coupled with 
those of signiﬁcant weight gain with olanzapine versus ziprasi-
done in comparative studies, warrant investigation in longer-
term trials.
PCV2
COMBINED LIPID GOAL ATTAINMENT IN THE MANAGED
CARE SETTING
Sarawate C1, Bullano MF1, Cziraky MJ1,Willey VJ1, Schrader BJ2,
Charland SL2, Stanek EJ2
1Health Core, Inc, Newark, DE, USA; 2Kos Pharmaceuticals, Inc,
Weston, FL, USA
OBJECTIVES: To evaluate combined low- and high-density
lipoprotein-cholesterol (LDL-C/HDL-C) and triglyceride (TG)
goal attainment and associated therapy over an extended time
period. METHODS: A retrospective cohort analysis using a 1.1
million member southeastern US managed care database.
Patients with a full lipid panel from October 1, 1999–September
39, 2000 (index lab), naive to lipid therapy and with health plan
eligibility 12 months pre and post-index lab were identiﬁed. Pre-
vention status was deﬁned as high-risk primary (age; men > 45
years, women > 55 years; HDL-C < 40mg/dL; hypertension diag-
nosis and therapy), or secondary (pre-index lab vascular event
or revascularization). Lipid goal targets were established using
NCEP ATP-III guidelines. Combined lipid (LDL - C + HDL - C
+ TG) goal attainment was assessed at index and then quarterly
during follow-up. The association between lipid goal achieve-
ment and prescribed therapy was assessed using multinomial
logistic regression. RESULTS: A total of 30,348 patients, with
92,690 lipid panels, were followed for a mean of 27 ± 8 months.
Mean age was 66 ± 12 years, 54% male, and prevention status
was classiﬁed as high-risk primary in 43% and secondary in
57%. Combined lipid goal attainment was observed in 25%,
46%, and 50% of patients at index, 12 and 36 months, respec-
tively. Forty-seven percent of these patients had isolated baseline
high LDL-C. Among the 50% of patients not attaining combined
lipid goals at 36 months, 85% had low HDL-C and/or elevated
TG. Lipid-altering therapy, primarily statin monotherapy (88%),
was prescribed in 30% of patients, after a post-index lag period
of 7 ± 8 months. Prescription of lipid-altering therapy was sig-
niﬁcantly associated with attainment of LDL-C goal (p < 0.05)
but not HDL-C or TG goals. CONCLUSIONS: In this managed
care setting, 50% of high-risk patients did not attain combined
lipid goals, largely due to undertreatment of low HDL-C and/or
elevated TG.
PCV3
USING HEALTH-RISK APPRAISAL DATA FOR ASSESSING
PREDICTORS OF HYPERTENSION TREATMENT
Brown JS1, Menzin J1, Manocchia M2
1Boston Health Economics, Inc, Waltham, MA, USA; 2Blue Cross Blue
Shield of Rhode Island, Providence, RI, USA
OBJECTIVES: The beneﬁts of hypertension therapy for patients
with elevated blood pressure (BP) are well established. The study
objective was to evaluate predictors of drug treatment for
patients with hypertension using a managed-care database that
links health risk appraisal (HRA) data with medical encounter
claims. METHODS: HRA data and physiological measurements
were collected during worksite wellness clinics held at employer
sites in 2002 in the Northeastern US. HRA information included
body mass index (BMI), family history of cardiovascular disease,
tobacco use, self-perceived health status, level of physical activ-
ity, and stages of change, among other measures. Clinical staff
collected BP measurements. Medical encounter and pharmacy
data were summarized for 2001 through 2003 for all clinic par-
ticipants and used to assess medication use and comorbidities.
Cohort selection criteria included elevated BP (diastolic 140
mmHg or higher or systolic 90mmHg or higher), medical insur-
ance eligibility for 2002 and 2003, HRA participation in 2002,
and no BP medication dispensed in 2001. The primary outcome
of interest was the likelihood of initiating antihypertensive drug
therapy in 2002 or 2003. Logistic regression was used to assess
predictors of treatment. RESULTS: The average age of clinic 
participants (n = 506) was 47 years, 59% were male, and 18%
received at least one hypertension medication during the study
period. The likelihood of treatment was positively associated
with BMI (p < 0.01), number of comorbidities (p < 0.001),
hypertension awareness (p < 0.001), self-reported depression or
stress (p = 0.03), and family history of cardiovascular disease (p
= 0.04). Treatment was inversely associated with male gender 
(p = 0.02), but not related to age, self-reported health status, level
of physical activity or tobacco use. CONCLUSION: The likeli-
hood of receiving treatment for hypertension depends on several
factors that rely on surveys, such as the HRA. Combining mul-
tiple data sources can facilitate outcomes research studies in
hypertension.
PCV4
VARIABLE PATIENT COMPLIANCE WITH STATINS AND
ASSOCIATED LIPID CONTROL AMONG CHINESE PATIENTS
WITH HIGH RISK FOR CORONARY HEART DISEASE
Cheng CW1,Woo KS2, Chan JC2,Tomlinson B2, You JH1
1The Chinese University of Hong Kong, Hong Kong, China; 2The
Chinese University of Hong Kong
Coronary heart disease (CHD) is one of the major causes of
death in Hong Kong. Medical non-compliance for patients
receiving statin therapy can cause sub-optimal control of serum
